CD4 and renal cell carcinoma: Furthermore, compared with the single shikonin treatment group, ipilimumab combined with shikonin significantly decreased the FoxP3+ Treg subpopulation in RCC-53 and enhanced the CD3+CD4+ T cells population in SKRC-17 and RCC-53 (Figures 5B, 6B).